<DOC>
	<DOCNO>NCT00547586</DOCNO>
	<brief_summary>The primary purpose study evaluate safety dose-response relationship N-methylnaltrexone bromide ( MOA-728 ) observe spontaneous bowel movement subject chronic pain , due malignant cancer , opioid-induced bowel dysfunction ( OIBD ) .</brief_summary>
	<brief_title>Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Adult outpatient opioidinduced bowel dysfunction chronic pain , due malignant cancer . Taking oral , transdermal , intravenous , subcutaneous opioids . Willingness discontinue prestudy laxative therapy use study permit rescue laxative . History chronic constipation initiation opioid therapy . Other GI disorder know affect bowel transit . Women pregnant , breastfeeding , plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>